Bristol Myers Squibb (BMY) Finished Goods (2010 - 2013)
Bristol Myers Squibb's (BMY) quarterly Finished Goods came in at $569.0 million in Q1 2013, up 13.57% year-over-year from $501.0 million in Q1 2012, and down 0.52% quarter-over-quarter from $572.0 million in Q4 2012.
Analysis
Bristol Myers Squibb (BMY) Finished Goods (2010 - 2013) Analysis & Trends
Bristol Myers Squibb (BMY) has reported Finished Goods for 4 consecutive years, with $569.0 million the latest figure, recorded in Q1 2013.
- On a quarterly basis, Finished Goods rose 13.57% year-over-year to $569.0 million in Q1 2013; TTM through Mar 2013 was $569.0 million, a 13.57% increase from a year earlier, with the FY2012 full-year figure at $572.0 million, up 19.67% from the prior year.
- Finished Goods was $569.0 million for Q1 2013 at Bristol Myers Squibb, down from $572.0 million in the prior quarter.
- Over five years, Finished Goods peaked at $572.0 million in Q4 2012 and troughed at $397.0 million in Q4 2010.
- A 4-year average of $484.7 million and a median of $489.5 million in 2011 frame the typical range for Finished Goods.
- Across the five-year window, Finished Goods increased 21.01% in 2012 and grew 13.57% in 2013, its largest moves.
- Over 4 years, Finished Goods stood at $397.0 million in 2010, then grew by 20.4% to $478.0 million in 2011, then gained by 19.67% to $572.0 million in 2012, then retreated by 0.52% to $569.0 million in 2013.
- The last three Finished Goods figures came in at $569.0 million (Q1 2013), $572.0 million (Q4 2012), and $533.0 million (Q3 2012), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 650.65 Bn | 629.89 Bn | 17.26 Bn |
| 2 | AbbVie | 466.34 Bn | 459.82 Bn | 12.70 Bn |
| 3 | Merck | 362.11 Bn | 355.02 Bn | 12.21 Bn |
| 4 | Novartis Ag | 267.81 Bn | 260.52 Bn | 11.24 Bn |
| 5 | Pfizer | 157.31 Bn | 145.91 Bn | 10.94 Bn |
| 6 | Bristol Myers Squibb | 128.75 Bn | 117.69 Bn | 9.25 Bn |
| 7 | Sanofi | 51.80 Bn | 44.84 Bn | 10.79 Bn |
| 8 | Revolution Medicines | 40.91 Bn | 40.91 Bn | - |
| 9 | BeOne Medicines | 39.65 Bn | 34.55 Bn | 1.53 Bn |
| 10 | Incyte | 25.18 Bn | 20.65 Bn | 1.57 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2013 | 569.00 Mn |
| Dec 31, 2012 | 572.00 Mn |
| Sep 30, 2012 | 533.00 Mn |
| Jun 30, 2012 | 503.00 Mn |
| Mar 31, 2012 | 501.00 Mn |
| Dec 31, 2011 | 478.00 Mn |
| Sep 30, 2011 | 443.00 Mn |
| Jun 30, 2011 | 437.00 Mn |
| Mar 31, 2011 | 414.00 Mn |
| Dec 31, 2010 | 397.00 Mn |